The goal of the study was to evaluate the efficacy in lowering intraocular pressure (IOP) with a trabeculectomy and an amniotic membrane transplant (AMT) compared with the standard trabeculectomy with ...

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial This study aimed to ...

Mitomycin C can be a cost-effective alternative to BCG as intravesical treatment for intermediate-risk nonmuscle-invasive bladder cancer at a time when BCG is in short supply. Mitomycin C has ...

In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...

Adding hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C to surgery for locally advanced colorectal cancer (CRC) significantly reduced the risk of locoregional recurrence, the ...

Intravesical chemotherapy involves a healthcare professional injecting chemotherapy medication directly into the bladder to treat cancerous tumors. “Intravesical” means “within the bladder.” ...

The FDA has approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The intravesical mitomycin formulation is ...

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Sub-Tenon injection of mitomycin C may be ...

The median number of BCG doses per patient was 9 in the combination arm and 16 in the monotherapy arm. Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin ...

UGN-102 achieved a 78% complete response rate at 3 months in the phase 3 ENVISION trial for recurrent low-grade NMIBC. The FDA's Oncologic Drugs Advisory Committee narrowly voted against the ...